
Quarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Financial Statements 2011-2025 | CALT
Annual Financial Statements Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
966 M | 606 M | - | - | 106 M | - | - | - | - | - | - |
Shares |
50.8 M | 22.4 M | - | - | 33.2 M | - | - | - | - | - | - |
Historical Prices |
19.7 | 28.1 | - | - | - | - | - | - | - | - | - |
Net Income |
-510 M | -433 M | -32.6 M | -132 M | -86.8 M | -56.9 M | -51 M | - | - | - | - |
Revenue |
- | 874 K | 185 M | - | - | - | - | - | - | - | - |
Operating Income |
-524 M | -380 M | -28 M | -132 M | - | - | - | - | - | - | - |
EBITDA |
-524 M | -377 M | -26.1 M | -133 M | -84.6 M | -56.4 M | -51.3 M | - | - | - | - |
Operating Expenses |
- | - | 213 M | 133 M | 84.7 M | 56.5 M | 51.4 M | - | - | - | - |
General and Administrative Expenses |
390 M | 142 M | 62.9 M | 133 M | 64 M | 41.3 M | 43 M | - | - | - | - |
All numbers in SEK currency
Quarterly Income Statement Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | 52.4 M | - | - | 49.9 M | 49.9 M | - | - | 40.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | - | - | -207 M | - | - | -163 M | -133 M | - | - | -61.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 49.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | - | -208 M | - | - | -159 M | -151 M | - | - | -66.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | -208 M | - | - | -159 M | -151 M | - | - | -66.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | - | 84.4 M | - | - | - | 18.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Main types of financial statements Calliditas Therapeutics AB (publ) CALTFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Calliditas Therapeutics AB (publ) plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.21 | 1.68 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
$ 2.67 | 0.19 % | $ 1.39 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
$ 4.35 | -3.12 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
$ 12.29 | -1.09 % | $ 629 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.57 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
$ 6.66 | -3.55 % | $ 413 M | ||
|
Harrow Health
HROW
|
$ 50.7 | 1.22 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
$ 1.27 | -1.32 % | $ 22.2 M | ||
|
OrganiGram Holdings
OGI
|
$ 1.7 | -5.31 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
$ 5.19 | -1.71 % | $ 683 M | ||
|
Bausch Health Companies
BHC
|
$ 7.16 | -0.56 % | $ 2.61 B | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.66 | 0.83 % | $ 4.54 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 4.01 | -2.55 % | $ 56.4 M | ||
|
Rockwell Medical
RMTI
|
$ 0.8 | -7.01 % | $ 18.7 M | ||
|
Pacira BioSciences
PCRX
|
$ 26.17 | -1.3 % | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
$ 1.71 | -1.16 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
Veru
VERU
|
$ 2.22 | -7.71 % | $ 299 M | ||
|
Perrigo Company plc
PRGO
|
$ 13.94 | 0.87 % | $ 1.92 B | ||
|
ProPhase Labs
PRPH
|
$ 0.45 | -14.17 % | $ 7.13 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
$ 1.43 | -15.88 % | $ 6.17 M | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
$ 4.43 | -1.77 % | $ 133 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
$ 9.56 | -3.82 % | $ 679 M | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
$ 5.63 | -3.68 % | $ 230 M | ||
|
SCYNEXIS
SCYX
|
$ 0.63 | 6.75 % | $ 30.1 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Tilray
TLRY
|
$ 9.32 | -2.87 % | $ 5.76 B | ||
|
TherapeuticsMD
TXMD
|
$ 1.68 | -3.43 % | $ 17.5 M |